CRISPR Therapeutics AG (CRSP) stock
CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$40.15−0.22 (-0.54%)
Close on Nov 17, 2026Market cap $3.88BP/E –Yield –
CRISPR Therapeutics EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
CRISPR Therapeutics's EV/EBITDA was 10.7× on Jul 29, 2022, against 156.4× a year earlier.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2022 | Jul 29, 2022 | 10.7× | +3.0 |
| 2021 | Dec 31, 2021 | 7.8× | −148.6 |
| 2020 | Jul 31, 2020 | 156.4× | – |
See a number that looks wrong?